Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Pts w/Chronic Myeloid Leukemia
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Interview.
- Who it may be relevant to
- Registry conditions: Chronic Myeloid Leukemia, Chronic Phase Chronic Myelogenous Leukemia. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Impact of Personality on Adherence to Tyrosine Kinase Inhibitor Therapy in Patients With Chronic Myeloid Leukemia
Overview
This is an observational pilot study to examine the association between a patient's personality and adherence to tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia.
Detailed description
The purpose of this pilot study is to explore the association between personality and adherence to a specific type of oral cancer medication - tyrosine kinase inhibitor (TKI) - in patients with chronic myeloid leukemia (CML). 75 individuals with chronic phase CML who are being treated with TKIs will be recruited. Consenting patients will participate in a focused interview where TKI adherence, personality type, and quality of life and symptom burden will be assessed using validated questionnaires. Information on treatment response and the treating physician's perception of TKI adherence will be obtained from the electronic health record.
Interventions
- Other Interview
In-person interview with the study coordinator to complete study questionnaire.
Primary outcome measures
- Assessment of adherence to TKI medication [Time frame: Up to 1 year]
- Personality assessment [Time frame: Up to 1 year]
- Assessment of quality of Life [Time frame: Up to 1 year]
- Assessment of quality of Life and symptom burden [Time frame: Up to 1 year]
Eligibility criteria
Inclusion criteria
- 18 years of age or older
- Diagnosed with chronic myeloid leukemia (CML) and in the chronic phase (CML-CP)
- Currently being treated with one of four cancer medications - imatinib, dasatinib, bosutinib, or nilotinib
- A patient at the UCI Chao Family Comprehensive Cancer Center (CFCCC), or
- A member of a patient support group organized by the CML Buster Foundation
- Do not meet any of the criteria listed under "Exclusion Requirements"
Exclusion criteria
- Unable to read and speak English
- Impaired decisional capacity to consent
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Case-only
Study locations
United States · 1 center
- Chao Family Comprehensive Cancer Center University of California, Irvine — Orange
Identifiers
NCT: NCT06229860 · 3709 · UCI 23-110